Lilly sets up next-gen obesity battle with full phase 3 retatrutide data

Live updates

1. 1h ago

   Eli Lilly Reports Phase 3 Retatrutide Obesity and Diabetes Data

   Eli Lilly has released full phase 3 trial data for retatrutide, its experimental triple agonist weight-loss drug. In an 80-week trial, adults with type 2 diabetes taking the highest dose of retatrutide lost an average of 18.8% of their body weight, compared to 5.1% for the placebo group. Across trials, the drug delivered an average weight loss of 50 pounds, with some individuals losing up to 60 pounds. Additionally, Eli Lilly reported mid-stage trial results for EloraTZP, a combination of eloralintide and tirzepatide.

   Why it matters

   Retatrutide is the first triple agonist of its kind to reach a phase 3 clinical trial, setting a new benchmark for obesity treatments. The latest data release highlights potential health benefits and robust weight reduction for patients managing both obesity and type 2 diabetes. Concurrently, Eli Lilly is advancing combination regimens that pair amylin analogues with Zepbound to push efficacy boundaries further.

   What is confirmed

   • Retatrutide is a triple agonist and the first of its kind to reach a phase 3 clinical trial.
   • Adults with type 2 diabetes taking the highest retatrutide dose lost an average of 18.8% of their body weight, versus 5.1% with placebo in an 80-week trial.
   • People with type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
   • Lilly's EloraTZP combination delivered greater weight loss and A1C reduction versus tirzepatide 15 mg in adults with obesity and type 2 diabetes.

   Still unconfirmed

   • Retatrutide could provide other important health benefits beyond weight loss.

   What to watch next

   • Regulatory submissions and filings for retatrutide based on phase 3 trial outcomes.
   • Further clinical data releases regarding the EloraTZP combination regimen.
   Sources used for this update (10)

   1. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
   2. NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
   3. Fierce Biotech — Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
   4. CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
   5. Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
   6. www.scientificamerican.com — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
   7. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
   8. Fierce Biotech — Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
   9. www.prnewswire.com — Lilly's triple agonist, retatrutide, delivered substantial ...
   10. theclinicaltimes.com — Lilly reports phase 3 retatrutide weight-loss results in ...
   confidence 100%